Ivana Gojo, MD
Enriched profileProfessor of Oncology · Johns Hopkins University School of Medicine
Ivana Gojo is Professor of Oncology at Johns Hopkins University School of Medicine. OpenAlex indexes 274 publications with 9,646 citations (h-index 53); ClinicalTrials.gov lists 9 registered studies with this person as an investigator.
Data verified 16 Oct 2026
Overview
Updated 16 Oct 2026
Ivana Gojo, M.D., is Professor of Oncology at Johns Hopkins University School of Medicine / Sidney Kimmel Comprehensive Cancer Center. The public record shows 274 publications with 9,646 citations (h-index 53), centered on Acute Myeloid Leukemia Research, Retinoids in leukemia and cellular processes, Hematopoietic Stem Cell Transplantation. It also documents an investigator role on 9 registered clinical trials, industry payments reported by 6 companies, 2 NIH-funded awards (2007–2019).
- Most recent indexed publication: 2026 · British journal of haematology
- Top research focus: Acute Myeloid Leukemia Research
- 9 registered trials on ClinicalTrials.gov
- Open Payments reporting from 6 companies
Generated from the cited public record · current as of 16 Oct 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 6 in PubMed.
Total citations across indexed works.
Hirsch index (OpenAlex). i10-index 118.
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 16 Oct 2026
Listed as an investigator on 9 registered studies on ClinicalTrials.gov. The most recent:
- Evaluate the Safety, Tolerability, Pharmacokinetic Profile, Efficacy of Bl-M11D1
Sponsor: SystImmune Inc.
- Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Industry payments
Updated 16 Oct 2026
6 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- TAIHO ONCOLOGY, INC.Program year20252 payments
- Geron CorporationProgram year20253 payments
- Astellas Pharma US IncProgram year20251 payment
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Anti-infectives
50.3%Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor36.4%Valacyclovir100%Part D≥14 patientsShort-acting sulfonamides7.3%Sulfamethoxazole-Trimethoprim100%Part D<11 patients+ 1 more class in this area
Cancer & immunology
17.6%Isocitrate Dehydrogenase 2 Inhibitor9.7%Idhifa100%Part D<11 patientsBCL-2 Inhibitor7.9%Venclexta100%Part D<11 patientsAntiparasitic
9.1%Antimalarial9.1%Atovaquone100%Part D<11 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
Updated 16 Oct 2026
2 NIH research awards on record, funded 2007–2019 per NIH RePORTER. The latest:
- The Johns Hopkins Translational Science Team for the ET-CTN
Johns Hopkins University
FY2019$1,639,503UM1CA186691 - The Johns Hopkins Translational Science Team for the ET-CTN
Johns Hopkins University
FY2018$2,209,015UM1CA186691 - The Johns Hopkins Translational Science Team for the ET-CTN
Johns Hopkins University
FY2017$300,000UM1CA186691
Congress activity
Updated 16 Oct 2026
46 congress contributions (2006–2025) across AACR, ASCO, ASH per OpenAlex. The most recent:
- DNMT3A, NPM1, and FLT3-ITD triple-mutated AML has a favorable prognosis in the era of FLT3 inhibitors
ASH Annual Meeting
ASH2025Co-author - Metronomic dose decitabine therapy for TP53 complex karyotype myeloid neoplasms
ASH Annual Meeting
ASH2025Co-author
Published abstracts are attributed via the same ORCID-disambiguated authorship as publications, so each is DOI-verified. Podium roles (invited talks, session chairs) and oral/poster type are added as program data is confirmed.
Publications
Updated 16 Oct 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- Outcome heterogeneity in CALR-mutated myeloproliferative neoplasms.
British journal of haematology
Article2026 - Magrolimab Plus Azacitidine Versus Placebo Plus Azacitidine in Patients With Untreated Higher-Risk Myelodysplastic Syndromes: The Phase III ENHANCE Study.
Journal of clinical oncology
Clinical Trial2026
Most-cited works
by citation count (OpenAlex)- 01
- 02Immune signature drives leukemia escape and relapse after hematopoietic cell transplantationArticle403 citations2019
- 03Myeloid cell factor–1 is a critical survival factor for multiple myelomaArticle368 citations2002
- 04Immune escape and immunotherapy of acute myeloid leukemiaArticle344 citations2020
- 05NCCN Guidelines Insights: Acute Myeloid Leukemia, Version 2.2021Article322 citations2021
Network
Updated 16 Oct 2026
The people this person publishes with most, by number of co-authored papers. Names link to their own profile when we have one.
Online presence
Updated 16 Oct 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/ivana-gojo-md
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →doximity.com ↗
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 16 Oct 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- Board certified in Hematology
American Board of Internal Medicine
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Editorial & leadership roles
journal and society appointments- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- Member
American Society of Hematology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Member
American Society of Clinical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗ - Member
American Association for Cancer Research
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Awards & honors
honors on the public record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Secondary affiliations
appointments beyond the home institution- Co-Director
Leukemia Drug Development Program, Johns Hopkins
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →profiles.hopkinsmedicine.org ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Kenneth Pienta, MD
Johns Hopkins University School of Medicine
Michelle Petri, MD
Johns Hopkins University School of Medicine
Harry Quigley, MD
Johns Hopkins University School of Medicine
Hagop Kantarjian, MD
The University of Texas MD Anderson Cancer Center
Jorge Cortes, MD
University of Alabama at Birmingham (UAB)
Ayalew Tefferi, MD
Mayo Clinic
Charles Sawyers, MD
Memorial Sloan Kettering Cancer Center